Here, we discuss preclinical and clinical findings in obesity and other therapeutic areas of interest for glucagon, the endogenous incretin hormones GIP and GLP‐1 and GLP‐1R agonists, as well as their actions when combined as dual and triple agonists. This evidence concerns the gene GCG and obesity disorder.